Aquila Biopharmaceuticals Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1
  • Investments
  • 1

Aquila Biopharmaceuticals General Information

Description

Manufacturer of human and animal healthcare products intended to enhance the immune response systems. The company develops and commercializes a range of proprietary products for use in treating, controlling and preventing infectious diseases, cancers, and autoimmune disorders using immune enhancement technologies, enabling companies to identify and present specific lipid-based antigens.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • 175 Crossing Boulevard
  • Framingham, MA 01702
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aquila Biopharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aquila Biopharmaceuticals‘s full profile, request access.

Request a free trial

Aquila Biopharmaceuticals Executive Team (1)

Name Title Board Seat Contact Info
Alison Taunton-Rigby Ph.D President & Chief Executive Officer
To view Aquila Biopharmaceuticals’s complete executive team members history, request access »

Aquila Biopharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 13-Apr-1998 000000000000000000 00.00 Medical Supplies
To view Aquila Biopharmaceuticals’s complete acquisitions history, request access »